570 related articles for article (PubMed ID: 28860717)
1. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
2. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
[TBL] [Abstract][Full Text] [Related]
3. Idursulfase in Hunter syndrome treatment.
Zareba G
Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
[TBL] [Abstract][Full Text] [Related]
5. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
6. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II).
Okuyama T; Tanaka A; Suzuki Y; Ida H; Tanaka T; Cox GF; Eto Y; Orii T
Mol Genet Metab; 2010 Jan; 99(1):18-25. PubMed ID: 19773189
[TBL] [Abstract][Full Text] [Related]
7. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
Wraith JE
Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
[TBL] [Abstract][Full Text] [Related]
11. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
[TBL] [Abstract][Full Text] [Related]
13. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
[TBL] [Abstract][Full Text] [Related]
14. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
[TBL] [Abstract][Full Text] [Related]
17. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.
Chung YK; Sohn YB; Sohn JM; Lee J; Chang MS; Kwun Y; Kim CH; Lee JY; Yook YJ; Ko AR; Jin DK
Glycoconj J; 2014 May; 31(4):309-15. PubMed ID: 24781369
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
[TBL] [Abstract][Full Text] [Related]
19. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
